Select a Region North America

Expertise

Greg Skalicky

President

Expertise:

Commercialization

As President of EVERSANA, Greg is responsible for accelerating the company’s growth and ensuring the success of all client commercialization efforts. With more than 25 years of executive leadership, Greg understands all facets of the pharmaceutical industry, spanning clinical operations to commercial success. Greg’s previous roles include Chief Enterprise Business Officer and Executive Vice President and General Manager at a global bio-pharmaceutical solutions organization, where he successfully managed business units and teams of several thousand employees. Skalicky holds a Bachelor of Science in Biology from Temple University and a Master of Business Administration from Villanova University. He is an active member across several industry panels and consortiums.

Articles by Greg Skalicky

Bending the “Commercialization Curve” in Large Pharma

If the last few years have taught us anything, it’s that it’s more important than ever to embrace change and new ways to bring therapies to patients. This is especially the case when considering commercialization and globalization in the life sciences and pharmaceutical industries.   Although many would agree that this adaptation is important, we haven’t seen much change in the last 30 years in the way larger companies are bringing drugs to market. Failure to adapt and embrace new ways of doing things can cause significant challenges for the industry, creating downstream impacts across healthcare, the largest of which is on patients.   Despite these pressures, and with the […]

Overcome In-Licensing Barriers to Increase Throughput of Assets

In-licensing is an important growth channel for pharmaceutical companies as they continue to seek more catalysts for growth. In-licensing is used to expand or consolidate a company’s position in a therapy area but can oftentimes be limited by internal restraints. Common Barriers to In-Licensing: Capacity and Capability Constraints Many times, companies are limited in in-licensing more clinically and commercially viable assets due to commercial capacity and capability constraints. In fact, observations from recent due diligence efforts indicate companies eliminate at least 20-30% of potentially viable assets due to not having enough resources to commercialize the asset or not having the unique capabilities necessary to commercialize based on asset or market […]

Reinventing Launch: The Gold Standard Of Drug Commercialization

In a world that is rapidly changing, we must evolve beyond traditional strategies to create true impact for patients. EVERSANA’s complete end-to-end commercialization model enables manufacturers to bring their drug to market at a fraction of the cost of “going it alone” or partnering with another pharmaceutical company.

Interested in scheduling a meeting or speaking event?

お問い合わせ